Abstract
Although perturbed lipid metabolism can often lead to skin abnormality, the role of phospholipase A2 (PLA2) in skin homeostasis is poorly understood. In the present study we found that group X-secreted PLA2 (sPLA2-X) was expressed in the outermost epithelium of hair follicles in synchrony with the anagen phase of hair cycling. Transgenic mice overexpressing sPLA2-X (PLA2G10-Tg) displayed alopecia, which was accompanied by hair follicle distortion with reduced expression of genes related to hair development, during a postnatal hair cycle. Additionally, the epidermis and sebaceous glands of PLA2G10-Tg skin were hyperplasic. Proteolytic activation of sPLA2-X in PLA2G10-Tg skin was accompanied by preferential hydrolysis of phosphatidylethanolamine species with polyunsaturated fatty acids as well as elevated production of some if not all eicosanoids. Importantly, the skin of Pla2g10-deficient mice had abnormal hair follicles with noticeable reduction in a subset of hair genes, a hypoplasic outer root sheath, a reduced number of melanin granules, and unexpected up-regulation of prostanoid synthesis. Collectively, our study highlights the spatiotemporal expression of sPLA2-X in hair follicles, the presence of skin-specific machinery leading to sPLA2-X activation, a functional link of sPLA2-X with hair follicle homeostasis, and compartmentalization of the prostanoid pathway in hair follicles and epidermis.
Keywords: Eicosanoid, Mouse, Phospholipase A, Phospholipid, Skin
Introduction
Hair follicle morphogenesis is regulated by interactions between epidermal keratinocytes committed to hair follicle differentiation and dermal fibroblasts committed to form the dermal papilla of the developing hair follicles (1–3). These epithelial-mesenchymal interactions culminate in the formation of the hair shaft, which is surrounded by the multilayered inner root sheath (IRS)3 and outer root sheath (ORS), the latter being the outermost concentric layer of epithelial cells. Hair follicles undergo repeated cycles of growth (anagen), regression (catagen), and rest (telogen) during their life span. Distinct signaling pathways and transcription factors control hair follicle morphogenesis, postnatal hair growth, and hair cycling in a coordinated manner. Accordingly, disturbance in the expression or function of these genes by point mutations, transgenic (Tg) overexpression, or targeted disruption often culminates in a hairless phenotype. Because hair loss due to various factors, such as diseases, hormonal imbalance, and drug regimens, affects a large population worldwide, there are compelling reasons to understand the fundamentals of hair biology.
Current evidence suggests that, in addition to a variety of cytokines and growth factors (4, 5), lipids also play important roles in hair follicle homeostasis (6, 7). The PGE2 receptors EP3 and EP4 are expressed in the dermal papilla and ORS of hair follicles (8, 9). COX-2 displays a trend of hair cycle-synchronized expression in the ORS of hair follicles (9), and skin-specific Tg overexpression of COX-2 leads to delayed emergence of hair shafts, reduced hair follicle density, and alopecia (10, 11). Elevated expression of EP4 and COX-2 has been found in biopsy samples from patients with scarring alopecia (12). These observations suggest that excess PGE2 signaling is detrimental for hair homeostasis. Autosomal recessive wooly hair with hypotrichosis, a type of nonsyndromic human alopecia, is caused by mutations of either LIPH, which encodes a phospholipase A1 that produces lysophosphatidic acid (LPA) from phosphatidic acid, or P2Y5, which encodes the LPA6 receptor (7), implying the importance of LPA signaling in hair growth. In addition, hair abnormalities have often been associated with mutations or altered expression of genes for lipid synthesis, degradation, signaling, or transport (13–16), further highlighting the close connection between lipid perturbation and hair disorders.
Because phospholipase A2 (PLA2) regulates the first step of enzymatic cascades, leading to biosynthesis of lipid mediators, and also plays an important role in membrane homeostasis, it is tempting to speculate that certain PLA2 enzymes would participate in the regulation of hair development. PLA2s have been classified into several groups, including secreted PLA2s (sPLA2s), Ca2+-dependent cytosolic PLA2s, Ca2+-independent PLA2s, platelet-activating factor acetylhydrolases, and lysosomal PLA2s (17). Although recent studies employing mice with gene targeting of intracellular and extracellular PLA2s have delineated their non-redundant functions in various biological events (17, 18), none of these knock-out mice have developed skin abnormalities. The notion that sPLA2 may play a role in skin biology originally arose from studies employing Tg mice overexpressing group IIA sPLA2 (sPLA2-IIA), which develop permanent alopecia and epidermal hyperplasia (19). However, the fact that the mouse strain used so far (C57BL/6) intrinsically lacks sPLA2-IIA because of a frameshift mutation in its gene (20) has raised a question as to the physiological relevance of the hairless phenotype in PLA2G2A-Tg mice. Although mammalian genomes encode genes for 10 catalytically active sPLA2 isoforms that exhibit unique tissue and cellular localizations and enzymatic properties (17, 18), it remains uncertain whether other sPLA2 isoforms are expressed and play roles within a skin niche.
Group X sPLA2 (sPLA2-X) is the most active sPLA2 isoform that can hydrolyze phospholipids in the mammalian cell membrane (21). sPLA2-X is synthesized as an enzymatically inactive zymogen, and proteolytic cleavage of the N-terminal propeptide leads to its conversion into the active form (22). Recent studies using Pla2g10-deficient mice have revealed its roles in TH2-biased asthma (23), ischemia/perfusion-induced myocardial injury (24), sperm fertility (25), adrenal corticosterone secretion (26), adiposity (27), and aortic aneurysm (28). In the present study, we found that Tg overexpression of sPLA2-X in mice resulted in skin abnormalities characterized by alopecia, unusual hair cycling, and epidermal and sebaceous gland hyperplasia, accompanied by aberrant hydrolysis of phosphatidylethanolamine (PE) and increased synthesis of some eicosanoids. More importantly, endogenous sPLA2-X was spatiotemporally expressed in the anagen hair follicles of mouse skin, and the skin of Pla2g10-deficient mice had abnormal hair follicles with reduced hair growth and hypoplasic ORS. Thus, our results highlight a novel role of sPLA2-X in hair homeostasis within a highly restricted and specialized skin compartment, the hair follicle.
EXPERIMENTAL PROCEDURES
Animals
All procedures involving animals were approved by the Institutional Animal Care and Use Committees of the Tokyo Metropolitan Institute of Medical Science and of Showa University in accordance with the Standards Relating to the Care and Management of Experimental Animals in Japan. The strategy for the generation and maintenance of Tg mice overexpressing PLA2G10 under the β-actin promoter was reported previously (29). All the PLA2G10-Tg mice were inbred with C57BL/6 mice. Mice lacking sPLA2-X (Pla2g10−/−) (24) and phospholipase Cδ1 (Plcd1−/−) (30) were described previously.
RT-PCR
Synthesis of cDNAs was performed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). PCR reactions were carried out using GeneAmp Fast PCR system (Applied Biosystems) on the ABI9800 Fast Thermal Cycler (Applied Biosystems) with a primer pair that could amplify both mouse Pla2g10 and human PLA2G10 mRNAs (5′-GACGCCATTGACTGGTGCTGC-3′ and 5′-AGTTCTTGGCATTTGTTCTCTGC-3′). For quantitative RT-PCR, PCR reactions were carried out using Power SYBR Green PCR system (Applied Biosystems) or TaqMan Gene Expression System (Applied Biosystems) on the ABI7700 Real Time PCR system (Applied Biosystems). The relative abundance of transcripts was normalized with constitutive expression of 18 S ribosomal RNA or β-actin mRNA. The oligonucleotide primers and probes (Roche Applied Science) used for quantitative RT-PCR are listed in supplemental Table S1.
Measurement of PLA2 Activity
Tissues were soaked in 10 volumes of 20 mm Tris-HCl (pH 7.4) and then homogenized with a Polytron homogenizer. The homogenates were centrifuged at 10,000 × g for 10 min. PLA2 activities in the supernatant were assayed by measuring the amounts of radiolabeled linoleic acid released from the substrate 1-palmitoyl-2-[14C]linoleoyl-PE (PerkinElmer Life Sciences). The substrate in ethanol was dried under a stream of N2 and dispersed in water by sonication. Each reaction mixture (total volume 250 μl) consisted of appropriate amounts of the required samples, 100 mm Tris-HCl (pH 7.4), 4 mm CaCl2, and 1 μm substrate. After incubation for 30 min at 37 °C, [14C]linoleic acid was extracted, and the radioactivity was quantified with a liquid scintillation counter as described previously (31). Protein contents were determined by BCA protein assay (Pierce).
Immunoprecipitation and Western Blotting
Rabbit polyclonal and mouse monoclonal anti-human sPLA2-X antibodies were gifted from Dr. Michael Gelb (University of Washington, Seattle, WA) and Dr. Shinji Hatakeyama (Novartis Pharma, Tsukuba, Japan), respectively. Immunoprecipitation and immunoblotting were performed using these antibodies as described previously (32). In brief, a monoclonal antibody for human sPLA2-X (7E2F11) or control mouse IgG1 (2 mg) was conjugated with 0.5 ml of formyl cellurofine (Seikagaku Kogyo). The beads (20 μl) were incubated with 250 μl of skin homogenates obtained from PLA2G10-Tg or control mice at 4 °C overnight. After centrifugation, the beads were washed 5 times with 1 ml of PBS and boiled for 5 min in 20 μl of sodium SDS-PAGE sample buffer with β-mercaptoethanol. Then the resulting supernatants were applied to 12.5% SDS-PAGE gels, and separated proteins were transferred to nitrocellulose membranes. The membranes were subjected to immunoblotting with rabbit anti-human sPLA2-X polyclonal antibody as described previously.
Histochemistry
Immunohistochemistry of mouse tissue sections was performed as described previously (33). In brief, skin samples were fixed with 100 mm phosphate buffer (pH 7.2) containing 4% paraformaldehyde and embedded in paraffin, sectioned, mounted on glass slides, deparaffinized in xylene, and rehydrated in ethanol with increasing concentrations of water. Hematoxylin and eosin staining was performed on 5-μm thick cryosections. For immunofluorescence, the tissue sections (5 μm) were incubated with 1× Blockace (DS Pharma BioMedical) in PBS for 30 min, washed 3 times with PBS for 5 min each, and incubated with rabbit antibody to mouse loricrin, filaggrin, cytokeratin 1, or cytokeratin 5 (Covance) at 1:1000–2000 dilution in 10× dilution of Blockace overnight at 4 °C. Sections were then washed 3 times with PBS for 5 min each and incubated with Alexa Fluor 647-labeled goat anti-rabbit IgG antibody (Molecular Probes) diluted to 1:1000 at 20 °C for 1 h. Counterstaining was performed with 4,6-diamino-2-phenylindole (DAPI) (Vector). Stained sections were analyzed with a confocal laser scanning microscope (LSM510 META, Carl Zeiss).
Electrospray Ionization Mass Spectrometry (ESI-MS)
Tissues were soaked in 10 volumes of 20 mm Tris-HCl (pH 7.4) and then homogenized with a Polytron homogenizer. Lipids were extracted from the homogenates by the method of Bligh and Dyer (34). The analysis was performed using a 4000Q-TRAP quadrupole-linear ion trap hybrid mass spectrometer (Applied Biosystems/MDS Sciex) with an Ultimate 3000 HPLC system (DIONEX Company) combined with an HTC PAL autosampler (CTC Analytics). The extracted lipids were subjected to electrospray ionization mass spectrometry analysis by flow injection (typically 3 nmol of phosphorus equivalent in the positive ion mode and 0.6 nmol of phosphorus equivalent in the negative ion mode) without liquid chromatography separation. The mobile phase composition was acetonitrile/methanol/water (6:7:2, v/v/v) (plus 0.1% ammonium formate (pH 6.8)) at a flow-rate of 10 μl/min. The scan range of the instrument was set at m/z 200–1000 at a scan speed of 1000 Da/s. The trap fill-time was set at 1 ms in the positive ion mode and at 20 ms in the negative ion mode. The ion spray voltage was set at 5500 V in the positive ion mode and at −4500 V in the negative ion mode. Nitrogen was used as curtain gas (setting of 10, arbitrary units) and as collision gas (set to “high”). The declustering potential was set at 100 V in the positive ion mode and at −100V in the negative ion mode. The collision energy in ESI-MS and ESI-MS/MS analyses were optimized according to the desired experiments. The method to detect the proper precursor ions and neutral losses derived from phospholipids in ESI-MS/MS analysis was described previously (35, 36).
For the assay of oxygenated lipids using LC-ESI-MS/MS analysis, tissues were soaked in ten volumes of methanol and then homogenized with a Polytron homogenizer. After overnight incubation at −20 °C, H2O was added to the mixture to give a final methanol concentration of 10% (v/v). d8-Labeled arachidonic acid (AA) (Cayman Chemicals) was added as an internal standard. The oxygenated lipids in the supernatant were extracted using Sep-Pak C18 cartridges (Waters). The LC-ESI-MS/MS analysis was performed using a 4000Q-TRAP quadrupole linear ion trap hybrid mass spectrometer (Applied Biosystems/MDS Sciex) with ACQUITY Ultra Performance LC® (Waters). The sample was applied to the ACQUITY UPLCTM BEH C18 column (1 × 150-mm inner diameter, 0.17-μm particle) and then to ESI-MS/MS analysis. The samples injected by the autosampler (10 μl) were directly introduced and separated by a step gradient with mobile phase A (water containing 0.1% (v/v) formic acid) and mobile phase B (acetonitrile:methanol = 4:1 v/v) at a flow rate of 50 μl/min and a column temperature of 30 °C. The specific detection of individual lipids was performed by multiple reaction monitoring (37).
Measurement of PGE2
Tissues were soaked in 10 volumes of methanol and then homogenized with a Polytron homogenizer. After the homogenates were kept on −20 °C overnight, H2O was added to the reaction mix (final concentration, 10% (v/v) methanol). The lipids were extracted by Sep-Pak C18 cartridges using [3H]AA (GE Healthcare) as a calibrator of the sample recovery. After the columns were equilibrated with H2O and methanol, the methanol extracts were applied to Sep-Pac C18 columns. The columns were sequentially washed with H2O and then with hexane followed by elution of the bound lipids with methyl formate. The contents of PGE2 in skin were quantified with a PGE2 enzyme immunoassay kit (Cayman Chemical).
Microarray Gene Profiling
Total RNAs were isolated from the skin of PLA2G10-Tg and control mice (n = 4) or Pla2g10+/+ and Pla2g10−/− mice (n = 4) at P25 by use of TRIzol reagent (Invitrogen) and purified using an RNeasy mini kit (Qiagen). cRNA targets were synthesized and hybridized with Whole Mouse Genome Oligo Microarray according to the manufacturer's instructions (Agilent). The array slides were scanned with a Laser Scanner GenePix 4000B (Molecular Devices) using appropriate gains on the photomultiplier to obtain the highest intensity without saturation. Gene expression values were background corrected and normalized using the GenePix software (Molecular Devices).
Microdissection
Mouse skin samples (P8) were embedded in OCT compound, sectioned (10-μm thick), mounted on a DIRECTOR LMD slide (AMR Inc.), fixed with cold ethanol/acetic acid (19:1, v/v) for 5 min, and stained with toluidine blue. Laser-capture microdissection was performed on cryosections using Leica LMD6000 system (Leica). mRNA was extracted using RNeasy Micro Kit (Qiagen) from the isolated hair follicle or epidermis fraction. Quantitative RT-PCR reactions were carried out using TaqMan Gene Expression system as described above.
For lipid analyses, lipids were extracted from the hair follicle or epidermis fraction microdissected from replicate skin sections without fixation with ethanol/acetic acid solution. An aliquot of the extracted lipids was subjected to PGE2 enzyme immunoassay or to ESI-MS for quantification of phospholipids. The contents of PGE2 in the microdissected samples were normalized with those of phospholipids as described previously (38).
Transmission Electron Microscopy
Mouse skin was fixed with 1% glutaraldehyde, 4% paraformaldehyde, and 0.1 m phosphate buffer (pH 7.4) at 4 °C overnight. After a brief wash with PBS, post-fixation with 2% OsO4− in PBS was carried out for 1 h followed by gradual dehydration with ethanol. The skin was embedded in Poly/Bed812 EPON (Polyscience). Thin serial sections (100-nm thick) were stained with uranyl acetate and lead acetate. Ultrastructures of the samples were examined at 80 kV with a JEM-1010 (Jeol Ltd.).
Statistics
Data were statistically evaluated by unpaired Student's t test at a significance level of p < 0.05.
RESULTS
Development of Alopecia in PLA2G10-Tg Mice
We previously established PLA2G10-Tg mice, in which the majority of overexpressed sPLA2-X protein existed as an inactive zymogen in most tissues (29). RT-PCR of dorsal skin from control and Tg mice at postnatal day 25 (P25) revealed that mRNA for sPLA2-X was endogenously expressed in control skin at a trace level (for details, see below), and it was markedly increased in Tg skin (Fig. 1A). Although PLA2G10-Tg mice appeared normal up to postnatal day 10 (Fig. 1B (P10)), complete loss of coat hairs was observed at 20–30 days (Fig. 1B (P20-P30)). Most Tg pups also had no or few whiskers (Fig. 1C), and their bald skin was wrinkled (Fig. 1, B (P20-P30) and D). After this hairless period, new pelage hairs appeared by P42 and were sustained for more than 1 year. After 18 weeks of age, however, the fur of PLA2G10-Tg mice appeared matted, lusterless, coarse, and ungroomed (Fig. 1B (18W)). Some older mice began to show thinning fur and small patchy areas of hair loss, particularly between the ears and on the back, where epidermal thickening was histologically obvious (data not shown). No apparent histological abnormality was found in various tissues of PLA2G10-Tg mice as they aged, including lung, liver, kidney, heart, small intestine, and colon (supplemental Fig. S1). Nevertheless, because the severe skin abnormalities in PLA2G10-Tg mice were particularly evident during P15-P30, in subsequent studies we focused on detailed phenotypic analyses of Tg mouse skin at this early stage.
The remarkable skin-specific phenotype of PLA2G10-Tg mice during the early period of life suggests that the proteolytic activation of sPLA2-X should have temporally occurred in the skin. In fact, a PLA2 enzymatic assay conducted using 1-palmitoyl-2-linoleoyl-PE as a substrate demonstrated that the activity in PLA2G10-Tg skin was increased 3- and 6-fold relative to that in control skin (reflecting the combined activities of various intrinsically present PLA2 enzymes) at P0 and P10, respectively (Fig. 1E). After reaching a peak value around P10, the PLA2 activity in Tg skin declined gradually to a level only <2-fold higher than that in control skin by 16 weeks. When skin homogenates were immunoprecipitated with mouse anti-human sPLA2-X monoclonal antibody followed by immunoblotting with rabbit anti-human sPLA2-X polyclonal antibody, three major bands with molecular masses of 11, 14, and 20 kDa as well as broad 21∼29-kDa bands were detected in PLA2G10-Tg skin, whereas they were undetectable in control skin (because mouse monoclonal anti-human sPLA2-X antibody failed to pull down endogenous mouse sPLA2-X) (Fig. 1F). Overall, the expression of immunoreactive sPLA2-X proteins in Tg skin was higher during P0–P10 than during P25–42 (Fig. 1F). As evaluated from the molecular sizes of authentic mature, zymogen and glycosylated forms of sPLA2-X (sPLA2-X overexpressed in PC12 cells (22); lane C in Fig. 1F), the 14-kDa species, whose intensity paralleled the PLA2 activity (Fig. 1E), appeared to correspond to the mature sPLA2-X. The smallest 11-kDa band might have been a cleaved fragment of sPLA2-X, although its precise identity requires further clarification. Nevertheless, the data for PLA2 activity (Fig. 1E) and immunoblotting (Fig. 1F) indicate that the mature (active) form of sPLA2-X was produced during a period when skin abnormality became evident in the Tg mice (see below).
PLA2G10-Tg Mice Display Unusual Hair Cycling, Hair Distortion, and Epidermal Hyperplasia
In mice, initial development of hair follicles starts from E13 to E18 and extends to P14 (growing phase or anagen) (1–3). Hematoxylin/eosin-stained sections of the mid-dorsal skin of newborn (P0) PLA2G10-Tg mice appeared entirely normal (supplemental Fig. S2). At P5, when wild-type follicles were in anagen, all follicular cell types were present, and the follicles had penetrated into the adipose layer, whereas fewer follicles could be found in the deeper regions of subcutaneous fat tissue in Tg mice. At P10, almost all pelage hair follicles of control mice had entered the final stage of anagen morphogenesis, having acquired their maximal length with hair shafts that had broken through the epidermis. Notably, many hair follicles in the skin of age-matched Tg mice had already entered catagen (regression phase), when retracting epithelial hair shafts had separated from the dermal papilla, indicating precocious entry of the Tg hair follicles into the growth-resting transition stage of the first postnatal hair growth cycle. Thereafter, hair follicles in control mice were synchronized in catagen at P15, telogen (resting phase) at P20, and transition from telogen to the next (second) anagen at P25 (1–3), whereas the majority of hair follicles in PLA2G10-Tg mice were still in telogen at P25. Moreover, although hair follicles in control skin were entirely in anagen at P30–P42, follicles exhibiting the telogen feature still existed in Tg skin, suggesting delayed transition of the Tg follicles to the next anagen. Thus, the effects of Tg expression of sPLA2-X culminate in abnormal hair cycling, with shortened anagen and prolonged catagen and telogen.
The dorsal skin of PLA2G10-Tg mice at P10–42, in which alopecia had developed (Fig. 1B), exhibited an abnormal hair follicle and epidermal histology (Fig. 2A and supplemental Fig. S2). The most obvious changes were fragile hairs (Fig. 2A, a), epidermal thickening (Fig. 2A, b), and enlarged hair follicles (Fig. 2A, c), which were already apparent at P15 and manifested at P25. Follicular enlargement appeared to result primarily from thickened ORS. At P25, some follicles had degenerated into cyst-like structures filled with keratinized debris and surrounded by multilayered epithelium (Fig. 2A, d). Both the squamous and suprabasal cellular layers, which appeared overall to be irregular and disorganized, contributed to the dramatic epidermal thickening. In PLA2G10-Tg mice, the uppermost layers of the epidermis displayed hyperkeratosis with a highly thickened stratum corneum, and hair shafts appeared thin, fragile, and often distorted. In addition, the sebaceous glands, an epidermal appendage budding from the upper ORS, of Tg mice displayed hyperplasia, which was characterized by the presence of numerous lobules consisting of sebocytes grouped around an enlarged sebaceous gland duct (Fig. 2A, e). In contrast, dermal infiltration of inflammatory cells and epidermal erosions, which are commonly observed in patients with inflammatory skin diseases such as psoriasis and atopic dermatitis, were scarcely evident in PLA2G10-Tg mice.
The histochemical data presented above indicate that overexpression of sPLA2-X in vivo leads to abnormal hair differentiation with perturbed hair cycling in the skin niche. To gain further molecular insight into these changes, we carried out quantitative RT-PCR with skin from PLA2G10-Tg mice and littermate controls at P25 (Fig. 2, B and C). In line with the hairless phenotype of PLA2G10-Tg mice, quantitative RT-PCR revealed markedly reduced expression of a subset of genes related to hair follicle differentiation and hair shaft formation, such as Shh (Sonic Hedgehog) and Bmp4 (bone morphogenetic protein 4), which regulate the proliferation and differentiation of matrix cells in the dermal papilla, and Msx2, Lef1, Foxn1, and Gata3, which are transcription factors required for proper differentiation of the hair shaft or IRS (1–3) (Fig. 2B). Quantitative RT-PCR analyses also showed marked increases (> ∼ 10-fold) in several mRNAs that could account for accelerated terminal differentiation of epidermal keratinocytes (Fig. 2C). These included mRNA for S100a9 (S100 family protein A; S100A), Flg1 (filaggrin 1), and Krt1 (keratin 1), which are enriched in the well differentiated stratum corneum and granulosum layers (2, 39). A moderate increase in Krt14 (keratin 14), a basal layer keratin (2, 39), was also notable, whereas the expression of Tgm1 (transglutaminase 1) and Tgm2, which are expressed in the stratum spinosum and basale (2, 39), did not differ appreciably between PLA2G10-Tg and control mice (Fig. 2C).
To verify whether the changes in these epidermal genes would be histologically relevant, we stained skin sections with antibodies for epidermal differentiation markers (2, 39). As expected, loricrin was present in the cornified layer (Fig. 2D, a), filaggrin in the cornified and granular layers (Fig. 2D, b), keratin 1 in the granular and spinous layers (Fig. 2D, c), and keratin 5 in a single basal layer (Fig. 2D, d) in the skin of control mice. Consistent with the quantitative RT-PCR analyses, increases in loricrin (Fig. 2D, e)-, filaggrin (Fig. 2D, f)-, keratin 1 (Fig. 2D, g)-, and keratin 5 (Fig. 2D, h)-positive cells were obvious in the epidermis of PLA2G10-Tg mice. Staining of keratin 5 extended focally to the upper epidermal layers as well as to the thickened hair follicular epidermal layers, and thickening of the loricrin-, filaggrin- and even keratin 1-positive signals in the stratum corneum was evident (Fig. 2D, e-g). Moreover, positive signals for these differentiation markers were also distributed in the cysts; loricrin and filaggrin were located in the innermost cell layers as well as in the keratinized debris within the cysts, and staining of keratin 1 and keratin 5 was positive in multiple layers of cells surrounding the cysts (Fig. 2D, arrowhead). These results indicate that the cysts resulted from abnormal and mis-directional (inward) differentiation of epidermal keratinocytes in PLA2G10-Tg skin.
Hair and epidermal abnormalities are often associated with dysregulated balance of proteases and protease inhibitors (40–48). Indeed, quantitative RT-PCR showed that the expression levels of Klk6 (kallikrein 6), Klk7 (kallikrein 7), and Ctsl (cathepsin L), but not Klk8 (kallikrein 8), Mstp1 (matriptase/MT-SP1), and furin (a subtilisin family protease), were increased significantly in PLA2G10-Tg skin relative to control skin (supplemental Fig. S3A). Considering that the amino acid sequence of the N-terminal cleavage site in sPLA2-X is similar to that cleaved by kallikreins or cathepsins (49), these inducible proteases identified thus far might contribute to the proteolytic activation of sPLA2-X in Tg skin. It was also noted that expression of the cysteine protease inhibitor Cst6 (cystatin M/E) and the serine protease inhibitor Spink5/Lekt1, abnormalities of which are associated with ichthyosis (46, 47), was increased 22.8- and 2.6-fold, respectively, in PLA2G10-Tg skin relative to control skin (supplemental Fig. S3B). These changes also reflect the hair and epidermal abnormalities in Tg mice.
Lipid Analysis of PLA2G10-Tg Skin
To identify the in vivo hydrolytic action of sPLA2-X on phospholipids, we next carried out ESI-MS/MS analysis of phospholipids using skin from PLA2G10-Tg mice and littermate controls at P25. Precursor ion scanning of choline-containing phospholipid molecular species revealed that the skin from control mice contained PC species mainly with C16:0-C16:0 (32:0), C16:0-C18:1 (34:1), and C18:0-C18:2 (36:2) (Fig. 3A, right panel) and trace levels of lysophosphatidylcholine species with C16:0 and C18:0 (Fig. 3A, left panel). Although sPLA2-X is the most potent sPLA2 isoform capable of acting on PC-rich membranes (21), none of these PC and lysophosphatidylcholine molecules was changed appreciably in PLA2G10-Tg mice in comparison with control mice. In contrast, neutral loss scanning of ethanolamine-containing phospholipid molecular species demonstrated that, of the major PE species (C18:0-C18:2 (36:2), C18:0-C20:4 (38:4), C18:1-C20:5 (38:6), and C18:0-C22:6 (40:6)), those with C18:0-C20:4 (38:4), C18:1-C20:5 (38:6), and C18:0-C22:6 (40:6) were reduced by ∼50% in the skin of PLA2G10-Tg mice relative to that of controls (Fig. 3B, right panel). The marked reduction of these PE species was accompanied by a concomitant increase in C18:0 and C18:1 lysophosphatidylethanolamine species (Fig. 3B, left panel). The compositions of phosphatidylserine and phosphatidylinositol did not differ between the genotypes (supplemental Fig. S4). Thus, sPLA2-X overexpressed in mouse skin preferentially hydrolyzed PE with polyunsaturated fatty acid (PUFA), including AA (C20:4), eicosapentaenoic acid (C20:5), and docosahexaenoic acid (C22:6).
We next performed LC-ESI-MS/MS analysis that was optimized for semiquantitative detection of various PUFAs and their oxygenated products (37). Consistent with the changes in PUFA-containing PE species, levels of free AA, eicosapentaenoic acid, and docosahexaenoic acid were nearly doubled in Tg mice relative to control mice (Fig. 4A). Of the AA metabolites detected so far, the levels of PGE2 and PGI2 (6-keto-PGF1α as a stable end-product) were increased substantially, those of PGD2 and 12- and 15-HETEs were unchanged, and those of 5- and 8-HETEs were decreased in the skin of PLA2G10-Tg mice relative to the controls (Fig. 4B). The increased amount of PGE2 in PLA2G10-Tg skin relative to control skin was confirmed by PGE2 enzyme immunoassay (Fig. 4C), thus validating the LC-ESI-MS/MS approach.
Because the profile of eicosanoids can be determined not only by the supply of free AA by PLA2s but also by the actions of downstream biosynthetic enzymes, we examined whether or not the expression of COXs, lipoxygenases (LOXs), and terminal synthases would be altered in PLA2G10-Tg skin. Quantitative RT-PCR showed 2∼3-fold increases in the expression levels of COX-1 (Ptgs1) and microsomal PGE synthase-1 (mPGES-1) (Ptges) in PLA2G10-Tg skin compared with control skin, whereas the expression levels of COX-2 (Ptgs2) and two other PGE synthases (Ptges2 and Ptges3) were unchanged (Fig. 4D), suggesting that the increased PGE2 production in PLA2G10-Tg skin (Fig. 4, B and C) may be derived mainly from the COX-1/mPGES-1 pathway. The expression levels of epidermal LOXs, including epidermal 12-LOX (Alox12e) and 12R-LOX (Alox12b), abnormalities of which have been shown to be associated with epidermal disorders (50, 51), were higher in PLA2G10-Tg skin than in control skin (Fig. 4E), consistent with the epidermal hyperplasia in Tg mice. Expression of 5-LOX (Alox5), an LOX isozyme responsible for leukotriene synthesis, was low, in agreement with the poor leukocyte infiltration (see above) and low 5-HETE production (Fig. 4B) in Tg skin.
Gene Expression Microarray Profiling of PLA2G10-Tg Skin
Microarray gene profiling of skin from PLA2G10-Tg mice in comparison with that from control mice yielded further supportive data for explaining the overall tendency of Tg skin to show hair follicle distortion and epidermal hyperplasia associated with hyperkeratosis in the absence of inflammation (Fig. 5 and supplemental Table S2). In agreement with the histologic and quantitative RT-PCR data (Fig. 2), microarray analysis showed markedly increased expression of genes that are enriched in the well differentiated stratum corneum and granulosum layers (e.g. S100a9, Lor, Sprr, Flg1, Krt1, and Krt10), moderate increases of basal keratins (e.g. Krt5 and Krt14), and minimal changes in the expression of genes associated with the stratum spinosum and basale (e.g. Tgm, Dsg, and Lama5) in PLA2G10-Tg mice (Fig. 5), thus accounting for the accelerated terminal differentiation of epidermal keratinocytes. Furthermore, in line with the hairless phenotype, the expression of genes involved in differentiation of hair follicles and hair shafts (e.g. Shh, Bmp4, Msx2, Lef1, Foxn1, HoxC13, and Gata3) as well as those for various hair keratins and hair keratin-associated proteins was dramatically decreased in PLA2G10-Tg skin relative to control skin (Fig. 5). In addition, the expression of a subset of genes for transcription factors that have been implicated in hair germ cell fate at the bulge (e.g. Ctnnb1, Tcf3, and Lhx2) was substantially lower in PLA2G10-Tg skin than in control skin. Finally, in agreement with the histological absence of inflammatory cells in the skin of PLA2G10-Tg mice (see above), neither microarray gene profiling (supplemental Table S2) nor quantitative RT-PCR (data not shown) revealed significant expression of proinflammatory cytokines, such as Il1b, Il4, Il6, Il12a, Il12b, Ifng, and Tnf (4, 5), in PLA2G10-Tg skin. Expression of a limited group of cytokines and chemokines reported to participate in skin biology, such as Il18, Ccl19, Ccl21, Ccl27, Cxcl14, and Cxcl16 (4, 5), showed substantial changes in PLA2G10-Tg skin relative to control skin (supplemental Table S2).
Endogenous sPLA2-X Is Spatiotemporally Expressed in Hair Follicles
On the basis of the aforementioned results, we speculated that endogenous sPLA2-X would be expressed somewhere in mouse skin, whose homeostasis is hampered by overexpression of this enzyme. However, expression of endogenous Pla2g10 mRNA in whole mouse skin was only at a trace level (Fig. 1A), and we did not observe apparent abnormality in the gross appearance of coat hairs in Pla2g10−/− mice (data not shown). To determine any detectable changes in the skin of Pla2g10−/− mice, we attempted to compare overall gene expression in Pla2g10−/− skin with that in Pla2g10+/+ skin by microarray gene profiling. We found that the expression levels of a panel of genes for hair keratins and hair keratin-associated proteins in the hair shaft were decreased 2∼3-fold in Pla2g10−/− skin compared with Pla2g10+/+ skin (Fig. 5). Expression of genes encoding several transcription factors for hair-associated genes, such as Foxn1, Hoxc13, Lef1, and Msx2, was also consistently lower in Pla2g10−/− skin than in Pla2g10+/+ skin. In contrast, expression of genes for the dermal papilla, hair germ, and epidermis as well as those related to inflammation (cytokines and chemokines) was mostly unaltered in Pla2g10−/− skin (Fig. 5 and supplemental Table S2). These results suggest that Pla2g10−/− mice may have some abnormalities in hair follicles but not in other skin compartments including epidermis, dermis, and sebaceous glands.
Several previous studies have reported that sPLA2-X is expressed in epidermal keratinocytes of human and mouse skins (52, 53). However, despite considerable effort, we were unable to detect sPLA2-X in mouse epidermis. Although we performed immunohistochemistry using five distinct anti-sPLA2-X antibodies, none of them showed epidermal localization of sPLA2-X at P0. Indeed, all of the antibodies used so far stained the epidermis of both Pla2g10+/+ and Pla2g10−/− mice equally (Fig. 6A), indicating that the epidermal staining was nonspecific. We noticed that, besides this pseudo-positive epidermal staining, sPLA2-X immunoreactivity was distributed in hair follicles of wild-type but not knock-out skin at P0 (Fig. 6A). Hair follicles appeared smaller in Pla2g10−/− mice than in Pla2g10+/+ mice (Fig. 6A), in agreement with the microarray results (Fig. 5). At P8 (mid-anagen), sPLA2-X immunoreactivity was localized in the outermost layer of hair follicles in Pla2g10+/+ but not in Pla2g10−/− mice (Fig. 6B). Staining of the hair shaft was again nonspecific, as it was also obvious in Pla2g10−/− skin (Fig. 6B). Analyses of the developmental expression of Pla2g10 mRNA in mouse skin by quantitative RT-PCR revealed that its expression was low at E17.5 (hair folliculogenesis stage), increased to a maximum expression level by P10 (anagen), declined to the basal level at P15–20 (catagen to telogen), and again began to increase at P25 (re-entry into the next anagen) (Fig. 6C). These results suggest that the expression of sPLA2-X is confined to hair follicles, being synchronized with hair cycling exhibiting a pattern of increased expression during the hair-growing anagen phase and decreased expression during the hair-retracting/resting catagen to telogen phases.
To further verify the hair follicular localization of sPLA2-X, hair follicles as well as epidermis were isolated by laser-capture microdissection from the mid-dorsal skin at P8 (Fig. 7A), a period of mid-anagen when the expression of sPLA2-X reached a nearly maximal level (Fig. 6C). Pools from hair follicles and epidermis obtained thus far were then subjected to quantitative RT-PCR for several marker genes known to localize specifically in each skin compartment. Preferential enrichment of S100a9, Krt1, and Krt14 in the epidermis fraction and Krt71, Krt85, and Krt33a in the hair follicle fraction indicated that the microdissection of each skin compartment had been successful (Fig. 7B). Importantly, Pla2g10 mRNA was detected in the hair follicle, but not in the epidermis, fraction (Fig. 7C), thus confirming the hair follicular localization of sPLA2-X in mouse skin. We then reasoned that if sPLA2-X indeed exists in hair follicles, its expression would be compromised in the other mouse line with hair abnormality. To this end, we examined the expression of Pla2g10 mRNA in the skin of phospholipase Cδ1-deficient (Plcd1−/−) mice, which exhibit postnatal distortion of hair follicles (30). As expected, the expression of Pla2g10 mRNA was hair cycle-dependent in Plcd1+/+ skin (in agreement with Fig. 6C), whereas it was markedly reduced in Plcd1−/− skin at each postnatal point (supplemental Fig. S5).
It was notable in wild-type mice that the two COX isoforms COX-1 (Ptgs1) and COX-2 (Ptgs2) were distributed predominantly in the epidermis and hair follicles, respectively, and that mPGES-1 (Ptges) was detected in the epidermis in marked preference to hair follicles, whereas other PGE synthases (Ptges2 and Ptges3) were evenly distributed in both fractions (Fig. 7C). These results suggest that the PGE2-biosynthetic enzymes are spatially segregated in distinct skin compartments and that the epidermal distribution of COX-1 and mPGES-1 could account for their increased expression in PLA2G10-Tg mice (Fig. 4C), where the epidermis is highly hyperplasic (Fig. 2).
Hair Follicle Abnormality in Pla2g10−/− Mice
Given that the expression of Pla2g10 mRNA in hair follicles reached a maximum level during anagen (Fig. 6C), we reassessed the hair histology of Pla2g10−/− and Pla2g10+/+ skins at the mid-anagen stage (P8). In contrast to the normal appearance of hair shafts in Pla2g10+/+ mice, those in Pla2g10−/− mice were frequently bent (Fig. 8A), although the number of hair follicles was similar between the genotypes (Fig. 8B). Quantitative RT-PCR of the hair follicle fraction, which had been isolated by microdissection (Fig. 7), revealed that the expression of the hair keratin Krt85, but not Krt6a and Krt17, was substantially lower in Pla2g10−/− mice than in Pla2g10+/+ mice (Fig. 8C), consistent with the microarray analysis (Fig. 5).
To further verify the ultrastructural abnormalities in hair follicles, we carried out transmission electron microscopy of mouse skin (Fig. 8, D–F). The hair follicle consists broadly of five distinctive layers: ORS, IRS, cuticle (Cu), hair cortex (Cx), and medulla (M) from the outermost to innermost layers. Each hair follicle has an ORS, which surrounds the follicle like a sleeve all the way to the bulb and is distinct from other epidermal components of the hair follicle. The cells of the ORS contain clearly vacuolated cytoplasm because of the presence of large amounts of glycogen. The cells at the periphery are more vacuolated than those in the axial border, which show a relatively intact cytoplasm. The store of glycogen in the ORS is probably utilized as a local supply of energy and materials for bulbar cell activities. In contrast, the ORS in Pla2g10−/− mice was noticeably thinner than that in wild-type mice (Fig. 8D and supplemental Fig. S6). Many of the vacuoles in ORS cells of Pla2g10−/− mice were disorganized and small relative to those of Pla2g10+/+ mice (Fig. 8E, a and d). Furthermore, in ORS cells of Pla2g10−/− mice, many of the mitochondria were swollen, and the pattern of tonofilaments was irregular (Fig. 8E, d). Because ORS cells at the mid-anagen stage are undergoing active cell division, the nuclei in ORS cells of Pla2g10+/+ mice showed a euchromatin structure (Fig. 8E, a). In contrast, the nuclei in the Pla2g10−/− ORS had a heterochromatin configuration, which is indicative of cell growth arrest or retardation (Fig. 8E, d). The companion layer, which is focally present in the innermost part of the ORS, is more flattened than the other cells of the ORS and does not contain glycogen. However, the border of the companion layer and ORS in the Pla2g10−/− follicles was vague compared with that in the Pla2g10+/+ follicles (Fig. 8, D and E, a and d). The IRS of the hair follicle constitutes a layered structure that extends from the base of the bulb to the isthmus, consisting of three distinct layers of epithelial cells known as Henle's layer (He), Huxley's layer (Hx), and IRS cuticle (Ci). The ultrastructure of these IRS layers did not differ between the genotypes (Fig. 8E, b and e). The hair shaft (cuticle, cortex, and medulla) is the cylindrical, keratinized, and often pigmented filament that can be seen in the upper skin, consisting mainly of dead cells that have turned into keratin filaments and binding material together with small amounts of water. Although structural abnormalities of the hair shaft were barely seen in Pla2g10−/− mice, melanin granules in the cortex were fewer in Pla2g10−/− mice than in Pla2g10+/+ mice (Fig. 8E, c and f). The bulb is a deep, bulbous portion of the follicle that surrounds the dermal papilla. Although the dermal papilla is responsible for directing and dictating the embryonic generation of a hair follicle, the bulb is the structure of actively growing cells that eventually produce the long fine hair cylinder. There were no morphologic differences in the hair bulb between the genotypes (Fig. 8F). Thus, even though endogenous sPLA2-X is dispensable for the central pathway for hair development, its absence in hair follicles results in ORS hypoplasia leading to modest hair shaft abnormality.
Unusual Up-regulation of PGE2 Synthesis in Hair Follicle of Pla2g10−/− Mice
Having established that sPLA2-X is a hair follicular sPLA2 that participates in the control of hair follicle homeostasis, we anticipated that the absence of this enzyme would decrease the level of hair follicular prostanoids. Unexpectedly, however, the level of PGE2 in the microdissected hair follicle fraction was unusually increased rather than decreased in Pla2g10−/− mice in comparison with Pla2g10+/+ mice (Fig. 9A). To gain insight into this unexpected elevation of PGE2 in Pla2g10−/− hair follicles, we examined the expression of enzymes in the PGE2 biosynthetic pathway in the microdissected hair follicle fraction by quantitative RT-PCR. Remarkably, the expression levels of COX-2 (Ptgs2) and to a lesser extent mPGES-1 (Ptges), but not other PGE synthases (Ptges2 and Ptges3) and the hair follicle PGE receptor EP4 (Ptger4), were increased in hair follicles of Pla2g10−/− mice relative to those of Pla2g10+/+ mice (Fig. 9B). In contrast, the expression of COX and PGES enzymes (Fig. 9C) as well as the level of PGE2 (Fig. 9A) in the epidermis fraction was similar between the genotypes. These results suggest that, unlike sPLA2-X overexpressed ectopically at a superphysiological level in PLA2G10-Tg mice (Fig. 4), endogenous sPLA2-X restricted to the anagen hair follicles is not linked to local PGE2 synthesis; rather, it may negatively regulate the expression of the PGE2 biosynthetic components (COX-2 and mPGES-1) through an unknown mechanism (see “Discussion”). Accordingly, the absence of sPLA2-X in hair follicles causes exaggerated PGE2 signaling, which may in turn perturb hair follicle homeostasis. This event seems to be compatible with hair defects observed in skin-specific COX-2-Tg mice (10, 11).
DISCUSSION
The hair cycle relies on an elegant and coordinated balance of stimulatory and inhibitory signals, which are spatially and temporally regulated in the hair follicle niche through orchestrated actions of various growth or differentiation factors and their inhibitors, transcription factors, and lipids (1–3). Clarification of the molecular mechanisms underlying hair regulation by these factors would provide opportunities for new therapeutic approaches to the treatment of individuals with hair loss, which can cause considerable psychological distress in most of those affected. In this study we have provided evidence that sPLA2-X is expressed in hair follicles in synchrony with the postnatal hair cycle and participates in hair quality control. To our knowledge, this is the first demonstration that this particular sPLA2 isoform plays a homeostatic role in a highly specialized skin compartment, i.e. the hair follicle, in addition to its reported roles in diverse pathophysiological events including asthma, ischemic myocardial injury, aneurysm, adiposity, adrenal steroid secretion, and fertility (17, 18, 23–28).
PLA2G10-Tg Mice Display Alopecia as Well as Epidermal Hyperplasia
Probably, the most striking evidence for the potential role of sPLA2 in the skin has been gained from studies employing PLAG2A-Tg mice, which exhibit almost total alopecia with no signs of inflammation (19), although the C57BL/6 mouse strain intrinsically lacks sPLA2-IIA as a result of a frameshift mutation of its gene (20). Although several previous studies have reported expression and localization of various sPLA2s in skin or cultured keratinocytes (52–55), variations in detection methodology and incomplete functional assessments have cast doubt on the specific roles of sPLA2s in complex skin niches.
In this study we found that Tg overexpression of sPLA2-X leads to alopecia (Figs. 1 and 2). This observation seems important as, unlike sPLA2-IIA that is absent from mouse skin, sPLA2-X is expressed endogenously in mouse hair follicles (Figs. 6 and 7). However, although PLA2G2A-Tg mice are permanently alopecic (19), the hairless phenotype of PLA2G10-Tg mice is evident only over a period corresponding to the catagen to telogen phase of the postnatal hair cycle. In contrast to the group II subfamily of sPLA2s, which are catalytically active once synthesized, sPLA2-X has an N-terminal propeptide that has to be removed before its activation (22, 49). Interestingly, the PLA2 enzymatic activity in skin homogenates of PLA2G10-Tg mice is transiently elevated before the hair loss, in accordance with the appearance of the mature form of sPLA2-X protein (Fig. 1), suggesting that proteolytic activation of sPLA2-X occurs in mouse skin during the early hair cycle. This temporary activation of sPLA2-X, as opposed to constitutive expression of active sPLA2-IIA, may account for the transient versus permanent appearance of skin abnormalities in PLA2G10- and PLA2G2A-Tg mice, respectively. In contrast to the remarkable skin phenotype, many other tissues in PLA2G10-Tg mice displayed no apparent histological abnormalities (supplemental Fig. S1), probably because the overexpressed sPLA2-X remains as an inactive zymogen unless inflammation occurs (29). Thus, mouse skin may have some particular protease machinery that leads to proteolytic processing of sPLA2-X under physiological conditions. In fact, unique and highly regulated protease/protease inhibitor networks are present in the skin, and disturbance of their balance could lead to faulty processing of hair follicle development and epidermal differentiation (40–48). Although the skin proteases responsible for sPLA2-X activation remain to be identified, kallikreins may be a candidate, as Tg overexpression of kallikreins leads to a similar skin phenotype (41), expression of kallikreins is markedly increased in PLA2G10-Tg skin (supplemental Fig. S3), and the propeptide sequence of sPLA2-X can be cleaved by kallikrein family proteases.
Our previous studies of Tg overexpression of sPLA2 isoforms in mice in combination with a lipidomics approach have led to the identification of potential in vivo actions of sPLA2-V on lung surfactant PC (29) and sPLA2-III on lipoprotein PC (32). However, although sPLA2-X is the most potent sPLA2 isoform with the ability to hydrolyze PC in intact mammalian cell membranes (56, 57), levels of PC as well as phosphatidylinositol and phosphatidylserine were unchanged in the skin of PLA2G10-Tg mice. Strikingly, hydrolysis of particular PE species giving rise to free AA, eicosapentaenoic acid, and docosahexaenoic acid, as well as C18:0 and C18:1 lysophosphatidylethanolamine, occurred in PLA2G10-Tg mice (Figs. 3 and 4), suggesting that sPLA2-X can preferentially hydrolyze PUFA-containing PE species in mouse skin. Given that sPLA2-X can hydrolyze both PC and PE equally in vitro (21, 56) and that PE usually resides in the inner leaflet of the plasma membrane, our results suggest that a pool of PUFA-containing PE species possibly secreted into the skin microenvironment or enriched in a particular membrane microdomain may become available for sPLA2-X-directed hydrolysis. Because PE is also a good substrate for sPLA2-IIA (6, 7), the shared skin phenotype between PLA2G2A-Tg and PLA2G10-Tg mice might primarily result from increased PE hydrolysis. Importantly, because no biochemical analysis of the alopecic phenotype of PLA2G2A-Tg mice has been conducted (19), the present study has provided the first biochemical insights into sPLA2-triggered phospholipid metabolism in the context of skin biology.
The AA produced by overexpressed sPLA2-X can be further converted to biologically active metabolites in the skin. Indeed, we found a notable increase of PGE2, a major COX metabolite produced by keratinocytes (55), in PLA2G10-Tg mice (Fig. 4). It has been reported that Tg overexpression of COX-2 in mouse skin results in increased PGE2 generation accompanied by hair loss as well as by abnormal epidermal differentiation leading to hyperplasia and dysplasia with little sign of inflammation (9), events that are strikingly similar to those observed in PLA2G10-Tg mice. PGE2 directly promotes keratinocyte proliferation in culture via EP2, a G protein-coupled PGE receptor, and Tg overexpression of EP2 also results in epidermal abnormality (59). Another PGE receptor, EP4, is expressed in the ORS of anagen hair follicles (8, 9), and elevated expression of EP4 as well as COX-2 is associated with human scarring alopecia (12). On the basis of these observations, it is likely that the overwhelming majority of PGE2 signaling may be linked, at least partly, with the hair follicle and epidermal abnormalities observed in PLA2G10-Tg mice. Additionally, coordinated increases in the expression of epidermal-type LOX enzymes, whose mutations or deletions cause epidermal abnormalities such as ichthyosis (50, 51), may be associated with epidermal hyperplasia in PLA2G10-Tg mice.
Pla2g10-deficient Mice Reveal the Intrinsic Role of sPLA2-X in Hair Follicle Homeostasis
The marked skin abnormalities manifested in PLA2G10-Tg mice prompted us to examine whether endogenous sPLA2-X would act as an intrinsic regulator of skin homeostasis. Our present studies employing immunohistochemistry as well as real-time RT-PCR analyses combined with a microdissection technique have provided evidence that it is in the hair follicle and not in the epidermis, as has been reported previously (52, 54), where sPLA2-X is intrinsically expressed. This is supported by the following observations. (i) immunohistochemical staining of sPLA2-X in mouse skin is distributed solely in the outermost layers of hair follicles, whereas it is absent in Pla2g10−/− mice (Fig. 6, A and B). (ii) Expression of Pla2g10 mRNA in mouse skin shows a pattern synchronized with hair cycling (Fig. 6C). (iii) In the skin of Plcd1−/− mice, which have distorted hair follicles (30), Pla2g10 mRNA expression is markedly reduced (supplemental Fig. S5). (iv) After laser-capture microdissection, Pla2g10 mRNA is enriched in the hair follicle fraction but not in the epidermis fraction (Fig. 7). (v) Pla2g10−/− mice display notable, albeit mild, abnormalities in hair follicles but not in the epidermis (Figs. 5, 8, and 9). Our finding that sPLA2-X is expressed in a restricted compartment within the skin niche (i.e. the ORS of hair follicles) in correlation with hair cycling, showing high expression during anagen and low expression during catagen-telogen, highlights an unexplored physiological role of this particular sPLA2 subtype in hair follicle homeostasis.
Interestingly, similar hair cycle-related expression profiles in the ORS or IRS of hair follicles have also been observed for several other hair-regulating factors that participate in the regulation of anagen-catagen or telogen-anagen transition and thereby in proper hair growth (60–67). Indeed, even though the hair phenotype of Pla2g10−/− mice appeared mild, our results revealed substantial reductions in a panel of genes encoding hair keratins and keratin-associated proteins as well as genes encoding the hair shaft-regulatory transcription factors (Fig. 5), suggesting delayed hair growth. In contrast, genes for the epidermis were unaffected by the lack of sPLA2-X, in agreement with the intrinsic distribution of this enzyme in the follicular ORS but not in the interfollicular epidermis. Moreover, in mid-anagen, the ORS above the hair bulb of Pla2g10−/− mice was thin, contained swollen mitochondria and fewer nutrient-rich vacuolar components, and showed evident growth retardation, perhaps causing focal twisting of subdermal hairs (Fig. 8). This is in contrast with the ORS of PLA2G10-Tg mice, which was strikingly hyperplasic (Fig. 2). Thus, sPLA2-X may contribute to the homeostasis of hair follicular ORS by promoting the proper growth of ORS keratinocytes. Perturbed growth and survival of ORS cells ultimately lead to the deficit in hairs (68).
Our present analysis employing laser-capture microdissection has demonstrated distinct compartmentalization of COX-1 and COX-2 in the epidermis and hair follicles, respectively, in mouse skin under physiological conditions (Fig. 7C). This finding is consistent with a previous study showing that COX-1 is localized predominantly in the interfollicular spinous and granular layers of the epidermis but not in follicular epithelial cells of cycling hair follicles, whereas COX-2 expression is hair cycling-dependent, becoming apparent in elongated hair germs and hair pegs in the course of pelage hair follicle morphogenesis, later on in the ORS of the distal and proximal hair follicles, declining in catagen and telogen, and then being re-induced in the ORS of anagen hair follicles (9). Because the expression of sPLA2-X in the ORS is also hair cycling-dependent (Fig. 6C), we had anticipated that sPLA2-X and COX-2 at the same location would be functionally coupled to provide a hair follicular pool of PGE2. Surprisingly, however, the level of hair follicular PGE2 was elevated rather than reduced by the absence of sPLA2-X. Consistent with this unexpected finding, the hair follicular expression of COX-2 and to a lesser extent mPGES-1 was substantially higher in Pla2g10−/− mice than in Pla2g10+/+ mice (Fig. 9). These results led us to conclude that endogenous sPLA2-X is not coupled with PGE2 synthesis in hair follicles; rather, its deficiency results in aberrant COX-2 expression leading to increased PGE2 synthesis, thereby mimicking the situation in skin-specific COX-2 Tg mice, which display hair abnormality (9, 58). Therefore, the mechanisms underlying hair abnormalities resulting from overexpression versus deletion of sPLA2-X appear to be distinct.
Although the molecular mechanism whereby deficiency of sPLA2-X leads to dysregulated COX-2 expression in hair follicles is still unclear, it is tempting to speculate that some lipid product(s) produced by sPLA2-X in this particular skin compartment may facilitate local induction of COX-2 and thereby overproduction of PGE2. LPA may be such a candidate, as mutations in the human P2Y5 gene (encoding LPA6 receptor) cause autosomal recessive wooly hair with hypotrichosis, although this speculation argues against the fact that the absence of LPA6 signaling perturbs the IRS rather than the ORS (7). It has been recently reported that sPLA2-X negatively regulates liver X receptor (LXR) or peroxisome proliferator-activating receptor (PPAR) signaling through production of PUFA in macrophages, adrenal cells, and adipocytes (26, 27, 69). Considering that the liver X receptor/peroxisome proliferator-activating receptor signaling pathway can diversely affect COX-2/mPGES-1-dependent PGE2 production (70–72) and that dysregulation of hair follicular PPARγ is linked to alopecia (12), sPLA2-X-dependent lipid product(s) might modulate PGE2 signaling through the lipid-sensing nuclear receptors in hair follicles. Alternatively, because sPLA2-X can potently hydrolyze lipoproteins (32) and because lipoprotein abnormality can cause hair loss (74), deficiency of sPLA2-X might locally perturb lipoprotein-mediated lipid transport within a hair follicle niche, thereby causing atrophy of nutrient-rich vacuoles in the ORS. Nevertheless, future identification of the sPLA2-X-regulated lipid pathway linked to ORS homeostasis would increase our understanding of the importance of lipids in skin biology. As an associated finding, we observed a notable decrease of melanin granules in hairs of Pla2g10−/− mice (Fig. 8). This may reflect the observation that sPLA2-X facilitates melanin synthesis and pigmentation through production of lysophosphatidylcholine in vitro (75). Alternatively, in view of the hypothetical sPLA2-X/lipid-sensing nuclear receptor connection mentioned above, regulation of melanin synthesis by PPARγ (76, 77) might underlie the decreased pigmentation of Pla2g10−/− hairs.
Future Prospects
Given that sPLA2-X essentially works as a hair modulator in anagen hair follicles, what is the significance of the abnormalities in the epidermis and sebaceous glands in PLA2G10-Tg mice? Lipids produced by epidermal keratinocytes and sebaceous glands play additional important roles in skin homeostasis (13, 14). Terminally differentiated epidermal keratinocytes secrete neutral lipids and fatty acids into the intercellular spaces of cornified envelopes, where they form a skin permeability barrier that prevents water loss from the body and also provides protection from invading pathogens and environmental toxins. Particularly, free fatty acids in the skin are important for acidification, integrity, and barrier function of the stratum corneum, and hydrolysis of phospholipids by certain sPLA2(s) has been proposed to be crucial for the supply of fatty acids into the interspace of corneocytes (78–80). Sebaceous glands produce and secrete lipid-rich sebum into the hair canal that empties out to the skin surface. In fact, expression of several lipogenic genes such as Elovl3 and Scd1, mutations of which result in cutaneous phenotypes (13, 14), was also elevated in PLA2G10-Tg skin (data not shown), suggesting a connection between sPLA2-directed perturbation of the lipid milieu and epidermal or sebaceous gland disorders. However, neither sPLA2-X (this study) nor sPLA2-IIA (9) is endogenously expressed in the epidermis or sebaceous glands of C57BL/6 mice, raising a question about the physiological relevance of the epidermal and sebaceous gland hyperplasia induced by Tg overexpression of a particular sPLA2 isoform.
The following possibilities are considered. First, considering that the hair follicle, epidermis, and sebaceous gland are contiguous, primary action of the overexpressed sPLA2-X on hair follicles might eventually alter the differentiation fate of skin stem cells at the bulge into upward (epidermal and sebaceous gland keratinocytes) rather than downward (follicular keratinocytes) directions, thereby altering the gene balance toward terminal epidermal differentiation over hair development. Indeed, hair abnormalities caused by deletion or mutations of various genes are often accompanied by epidermal and sebaceous gland abnormalities as well (73, 81, 82). Second, even though sPLA2-X is undetectable in the epidermis under sterile conditions, it might be induced in the epidermis under certain pathologic conditions such as dermatitis, infection, and cancer, where it might play some unidentified roles through modulation of epidermal phospholipid metabolism. Third, although the results of sPLA2-X overexpression on skin are not reciprocated by those of sPLA2-X deficiency (i.e. the defects in the knock-out mice are very modest compared with the effects in the Tg mice), the weak phenotype of sPLA2-X deficiency might be due to compensation by other sPLA2(s) expressed in mouse skin (52, 54). Indeed, the epidermal phenotype of PLA2G10-Tg mice might mirror the function of other sPLA2(s) that is intrinsically expressed in the epidermis, as we have recently found that a particular sPLA2 subtype (distinct from sPLA2-X) is highly expressed in mouse epidermis and that manipulation of its gene in mice causes striking epidermal abnormalities with dysregulated lipid signaling and epidermal barrier function, which are now under investigation.4
Finally, in view of previous reports showing that several sPLA2s including sPLA2-X are expressed in human epidermal keratinocytes (52, 53), sPLA2-X might participate in the homeostatic control of lipid machinery in the epidermis of humans. Nevertheless, the spatiotemporal expression profile of a full set of sPLA2s in healthy or diseased human skin would need careful reevaluation in the context of hair cycling, epidermal proliferation and differentiation, dermal inflammation, and wound healing. As a matter of fact, the spatiotemporal localization of sPLA2s in human hair follicles is entirely unknown. Given that millions of people suffer from hair loss that can be caused by various factors including genetic mutations, hormonal imbalances, immunological abnormalities, environmental exposures, or psychological stresses, full elucidation of the lipid networks regulated by sPLA2s in humans would be helpful for a novel strategy for treatment of alopecia.
Supplementary Material
Acknowledgments
We thank Dr. Michael Gelb (University of Washington, Seattle, WA) and Dr. Shinji Hatakeyama (Novartis Pharma, Tsukuba, Japan) for providing rabbit polyclonal and mouse monoclonal anti-human sPLA2-X antibodies, respectively.
This work was supported by grants-in aid for Scientific Research (to M. M.) and for Young Investigators (to K. Y., Y. T., and H. S.) from the Ministry of Education, Science, Culture, Sports, and Technology of Japan, SHISEIDO Grants for Scientific Research (to K. Y.), PRESTO (to M. M.), and CREST (to R. T.) from the Japan Science and Technology Agency, and the Cosmetology Research, Nakatomi, Uehara Toray and Mitsubishi Science Foundations (to M. M.).
The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1 and S2 and Figs. S1–S6.
K. Yamamoto and M. Murakami, unpublished observation.
- IRS
- inner root sheath
- ORS
- outer root sheath
- Tg
- transgenic
- PG
- prostaglandin
- LPA
- lysophosphatidic acid
- PLA2
- phospholipase A2
- sPLA2
- secreted PLA2
- sPLA2-IIA
- group IIA sPLA2
- sPLA2-X
- group X sPLA2
- PE
- phosphatidylethanolamine
- ESI
- electrospray ionization
- AA
- arachidonic acid
- PC
- phosphatidylcholine
- PUFA
- polyunsaturated fatty acid
- LOX
- lipoxygenase
- mPGES
- microsomal PGE synthase
- PPAR
- peroxisome proliferator-activating receptor.
REFERENCES
- 1. Alonso L., Fuchs E. (2006) J. Cell Sci. 119, 391–393 [DOI] [PubMed] [Google Scholar]
- 2. Fuchs E. (2007) Nature 445, 834–842 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Blanpain C., Fuchs E. (2009) Nat. Rev. Mol. Cell Biol. 10, 207–217 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Kupper T. S., Fuhlbrigge R. C. (2004) Nat. Rev. Immunol. 4, 211–222 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Lowes M. A., Bowcock A. M., Krueger J. G. (2007) Nature 445, 866–873 [DOI] [PubMed] [Google Scholar]
- 6. Colombe L., Vindrios A., Michelet J. F., Bernard B. A. (2007) Exp. Dermatol. 16, 762–769 [DOI] [PubMed] [Google Scholar]
- 7. Pasternack S. M., von Kügelgen I., Aboud K. A., Lee Y. A., Rüschendorf F., Voss K., Hillmer A. M., Molderings G. J., Franz T., Ramirez A., Nürnberg P., Nöthen M. M., Betz R. C. (2008) Nat. Genet. 40, 329–334 [DOI] [PubMed] [Google Scholar]
- 8. Torii E., Segi E., Sugimoto Y., Takahashi K., Kabashima K., Ikai K., Ichikawa A. (2002) Biochem. Biophys. Res. Commun. 290, 696–700 [DOI] [PubMed] [Google Scholar]
- 9. Müller-Decker K., Leder C., Neumann M., Neufang G., Bayerl C., Schweizer J., Marks F., Fürstenberger G. (2003) J. Invest. Dermatol. 121, 661–668 [DOI] [PubMed] [Google Scholar]
- 10. Neufang G., Furstenberger G., Heidt M., Marks F., Müller-Decker K. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 7629–7634 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Bol D. K., Rowley R. B., Ho C. P., Pilz B., Dell J., Swerdel M., Kiguchi K., Muga S., Klein R., Fischer S. M. (2002) Cancer Res. 62, 2516–2521 [PubMed] [Google Scholar]
- 12. Karnik P., Tekeste Z., McCormick T. S., Gilliam A. C., Price V. H., Cooper K. D., Mirmirani P. (2009) J. Invest. Dermatol. 129, 1243–1257 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Westerberg R., Tvrdik P., Undén A. B., Månsson J. E., Norlén L., Jakobsson A., Holleran W. H., Elias P. M., Asadi A., Flodby P., Toftgård R., Capecchi M. R., Jacobsson A. (2004) J. Biol. Chem. 279, 5621–5629 [DOI] [PubMed] [Google Scholar]
- 14. Zheng Y., Eilertsen K. J., Ge L., Zhang L., Sundberg J. P., Prouty S. M., Stenn K. S., Parimoo S. (1999) Nat. Genet. 23, 268–270 [DOI] [PubMed] [Google Scholar]
- 15. Cordeddu V., Di Schiavi E., Pennacchio L. A., Ma'ayan A., Sarkozy A., Fodale V., Cecchetti S., Cardinale A., Martin J., Schackwitz W., Lipzen A., Zampino G., Mazzanti L., Digilio M. C., Martinelli S., Flex E., Lepri F., Bartholdi D., Kutsche K., Ferrero G. B., Anichini C., Selicorni A., Rossi C., Tenconi R., Zenker M., Merlo D., Dallapiccola B., Iyengar R., Bazzicalupo P., Gelb B. D., Tartaglia M. (2009) Nat. Genet. 41, 1022–1026 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Klar J., Schweiger M., Zimmerman R., Zechner R., Li H., Törmä H., Vahlquist A., Bouadjar B., Dahl N., Fischer J. (2009) Am. J. Hum. Genet. 85, 248–253 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Lambeau G., Gelb M. H. (2008) Annu. Rev. Biochem. 77, 495–520 [DOI] [PubMed] [Google Scholar]
- 18. Murakami M., Taketomi Y., Girard C., Yamamoto K., Lambeau G. (2010) Biochimie 92, 561–582 [DOI] [PubMed] [Google Scholar]
- 19. Grass D. S., Felkner R. H., Chiang M. Y., Wallace R. E., Nevalainen T. J., Bennett C. F., Swanson M. E. (1996) J. Clin. Invest. 97, 2233–2241 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. MacPhee M., Chepenik K. P., Liddell R. A., Nelson K. K., Siracusa L. D., Buchberg A. M. (1995) Cell 81, 957–966 [DOI] [PubMed] [Google Scholar]
- 21. Murakami M., Kambe T., Shimbara S., Higashino K., Hanasaki K., Arita H., Horiguchi M., Arita M., Arai H., Inoue K., Kudo I. (1999) J. Biol. Chem. 274, 31435–31444 [DOI] [PubMed] [Google Scholar]
- 22. Masuda S., Murakami M., Takanezawa Y., Aoki J., Arai H., Ishikawa Y., Ishii T., Arioka M., Kudo I. (2005) J. Biol. Chem. 280, 23203–23214 [DOI] [PubMed] [Google Scholar]
- 23. Henderson W. R., Jr., Chi E. Y., Bollinger J. G., Tien Y. T., Ye X., Castelli L., Rubtsov Y. P., Singer A. G., Chiang G. K., Nevalainen T., Rudensky A. Y., Gelb M. H. (2007) J. Exp. Med. 204, 865–877 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Fujioka D., Saito Y., Kobayashi T., Yano T., Tezuka H., Ishimoto Y., Suzuki N., Yokota Y., Nakamura T., Obata J. E., Kanazawa M., Kawabata K., Hanasaki K., Kugiyama K. (2008) Circulation 117, 2977–2985 [DOI] [PubMed] [Google Scholar]
- 25. Escoffier J., Jemel I., Tanemoto A., Taketomi Y., Payre C., Coatrieux C., Sato H., Yamamoto K., Masuda S., Pernet-Gallay K., Pierre V., Hara S., Murakami M., De Waard M., Lambeau G., Arnoult C. (2010) J. Clin. Invest. 120, 1415–1428 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Shridas P., Bailey W. M., Boyanovsky B. B., Oslund R. C., Gelb M. H., Webb N. R. (2010) J. Biol. Chem. 285, 20031–20039 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Li X., Shridas P., Forrest K., Bailey W., Webb N. R. (2010) FASEB J. 24, 4313–4324 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Zack M., Boyanovsky B. B., Shridas P., Bailey W., Forrest K., Howatt D. A., Gelb M. H., de Beer F. C., Daugherty A., Webb N. R. (2011) Atherosclerosis 214, 58–64 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Ohtsuki M., Taketomi Y., Arata S., Masuda S., Ishikawa Y., Ishii T., Takanezawa Y., Aoki J., Arai H., Yamamoto K., Kudo I., Murakami M. (2006) J. Biol. Chem. 281, 36420–36433 [DOI] [PubMed] [Google Scholar]
- 30. Nakamura Y., Ichinohe M., Hirata M., Matsuura H., Fujiwara T., Igarashi T., Nakahara M., Yamaguchi H., Yasugi S., Takenawa T., Fukami K. (2008) FASEB J. 22, 841–849 [DOI] [PubMed] [Google Scholar]
- 31. Murakami M., Koduri R. S., Enomoto A., Shimbara S., Seki M., Yoshihara K., Singer A., Valentin E., Ghomashchi F., Lambeau G., Gelb M. H., Kudo I. (2001) J. Biol. Chem. 276, 10083–10096 [DOI] [PubMed] [Google Scholar]
- 32. Sato H., Kato R., Isogai Y., Saka G., Ohtsuki M., Taketomi Y., Yamamoto K., Tsutsumi K., Yamada J., Masuda S., Ishikawa Y., Ishii T., Kobayashi T., Ikeda K., Taguchi R., Hatakeyama S., Hara S., Kudo I., Itabe H., Murakami M. (2008) J. Biol. Chem. 283, 33483–33497 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Murakami M., Masuda S., Shimbara S., Ishikawa Y., Ishii T., Kudo I. (2005) J. Biol. Chem. 280, 24987–24998 [DOI] [PubMed] [Google Scholar]
- 34. Bligh E. G., Dyer W. J. (1959) Can. J. Biochem. Physiol. 37, 911–917 [DOI] [PubMed] [Google Scholar]
- 35. Houjou T., Yamatani K., Nakanishi H., Imagawa M., Shimizu T., Taguchi R. (2004) Rapid Commun. Mass. Spectrom. 18, 3123–3130 [DOI] [PubMed] [Google Scholar]
- 36. Taguchi R., Houjou T., Nakanishi H., Yamazaki T., Ishida M., Imagawa M., Shimizu T. (2005) J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823, 26–36 [DOI] [PubMed] [Google Scholar]
- 37. Sato H., Taketomi Y., Isogai Y., Miki Y., Yamamoto K., Masuda S., Hosono T., Arata S., Ishikawa Y., Ishii T., Kobayashi T., Nakanishi H., Ikeda K., Taguchi R., Hara S., Kudo I., Murakami M. (2010) J. Clin. Invest. 120, 1400–1414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Ikeda K., Taguchi R. (2010) Rapid Commun. Mass Spectrom. 24, 2957–2965 [DOI] [PubMed] [Google Scholar]
- 39. Candi E., Schmidt R., Melino G. (2005) Nat. Rev. Mol. Cell Biol. 6, 328–340 [DOI] [PubMed] [Google Scholar]
- 40. Klucky B., Mueller R., Vogt I., Teurich S., Hartenstein B., Breuhahn K., Flechtenmacher C., Angel P., Hess J. (2007) Cancer Res. 67, 8198–8206 [DOI] [PubMed] [Google Scholar]
- 41. Hansson L., Bäckman A., Ny A., Edlund M., Ekholm E., Ekstrand, Hammarström B., Törnell J., Wallbrandt P., Wennbo H., Egelrud T. (2002) J. Invest. Dermatol. 118, 444–449 [DOI] [PubMed] [Google Scholar]
- 42. Kishibe M., Bando Y., Terayama R., Namikawa K., Takahashi H., Hashimoto Y., Ishida-Yamamoto A., Jiang Y. P., Mitrovic B., Perez D., Iizuka H., Yoshida S. (2007) J. Biol. Chem. 282, 5834–5841 [DOI] [PubMed] [Google Scholar]
- 43. Leyvraz C., Charles R. P., Rubera I., Guitard M., Rotman S., Breiden B., Sandhoff K., Hummler E. (2005) J. Cell Biol. 170, 487–496 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Benavides F., Starost M. F., Flores M., Gimenez-Conti I. B., Guénet J. L., Conti C. J. (2002) Am. J. Pathol. 161, 693–703 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. List K., Szabo R., Wertz P. W., Segre J., Haudenschild C. C., Kim S. Y., Bugge T. H. (2003) J. Cell Biol. 163, 901–910 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Zeeuwen P. L., van Vlijmen-Willems I. M., Olthuis D., Johansen H. T., Hitomi K., Hara-Nishimura I., Powers J. C., James K. E., op den Camp H. J., Lemmens R., Schalkwijk J. (2004) Hum. Mol. Genet. 13, 1069–1079 [DOI] [PubMed] [Google Scholar]
- 47. Descargues P., Deraison C., Bonnart C., Kreft M., Kishibe M., Ishida-Yamamoto A., Elias P., Barrandon Y., Zambruno G., Sonnenberg A., Hovnanian A. (2005) Nat. Genet. 37, 56–65 [DOI] [PubMed] [Google Scholar]
- 48. Zeeuwen P. L. (2004) Eur. J. Cell Biol. 83, 761–773 [DOI] [PubMed] [Google Scholar]
- 49. Cupillard L., Koumanov K., Mattéi M. G., Lazdunski M., Lambeau G. (1997) J. Biol. Chem. 272, 15745–15752 [DOI] [PubMed] [Google Scholar]
- 50. Yu Z., Schneider C., Boeglin W. E., Brash A. R. (2005) Biochim. Biophys. Acta 1686, 238–247 [DOI] [PubMed] [Google Scholar]
- 51. Eckl K. M., Krieg P., Küster W., Traupe H., André F., Wittstruck N., Fürstenberger G., Hennies H. C. (2005) Hum. Mutat. 26, 351–361 [DOI] [PubMed] [Google Scholar]
- 52. Haas U., Podda M., Behne M., Gurrieri S., Alonso A., Fürstenberger G., Pfeilschifter J., Lambeau G., Gelb M. H., Kaszkin M. (2005) J. Invest. Dermatol. 124, 204–211 [DOI] [PubMed] [Google Scholar]
- 53. Schadow A., Scholz-Pedretti K., Lambeau G., Gelb M. H., Fürstenberger G., Pfeilschifter J., Kaszkin M. (2001) J. Invest. Dermatol. 116, 31–39 [DOI] [PubMed] [Google Scholar]
- 54. Gurrieri S., Fürstenberger G., Schadow A., Haas U., Singer A. G., Ghomashchi F., Pfeilschifter J., Lambeau G., Gelb M. H., Kaszkin M. (2003) J. Invest. Dermatol. 121, 156–164 [DOI] [PubMed] [Google Scholar]
- 55. Rys-Sikora K. E., Pentland A. P., Konger R. L. (2003) J. Invest. Dermatol. 120, 86–95 [DOI] [PubMed] [Google Scholar]
- 56. Hanasaki K., Ono T., Saiga A., Morioka Y., Ikeda M., Kawamoto K., Higashino K., Nakano K., Yamada K., Ishizaki J., Arita H. (1999) J. Biol. Chem. 274, 34203–34211 [DOI] [PubMed] [Google Scholar]
- 57. Bezzine S., Koduri R. S., Valentin E., Murakami M., Kudo I., Ghomashchi F., Sadilek M., Lambeau G., Gelb M. H. (2000) J. Biol. Chem. 275, 3179–3191 [DOI] [PubMed] [Google Scholar]
- 58. Muller-Decker K., Neufang G., Berger I., Neumann M., Marks F., Furstenberger G. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 12483–12488 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Sung Y. M., He G., Hwang D. H., Fischer S. M. (2006) Oncogene 25, 5507–5516 [DOI] [PubMed] [Google Scholar]
- 60. Hébert J. M., Rosenquist T., Götz J., Martin G. R. (1994) Cell 78, 1017–1025 [DOI] [PubMed] [Google Scholar]
- 61. Hansen L. A., Alexander N., Hogan M. E., Sundberg J. P., Dlugosz A., Threadgill D. W., Magnuson T., Yuspa S. H. (1997) Am. J. Pathol. 150, 1959–1975 [PMC free article] [PubMed] [Google Scholar]
- 62. Botchkarev V. A., Welker P., Albers K. M., Botchkareva N. V., Metz M., Lewin G. R., Bulfone-Paus S., Peters E. M., Lindner G., Paus R. (1998) Am. J. Pathol. 153, 785–799 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Foitzik K., Lindner G., Mueller-Roever S., Maurer M., Botchkareva N., Botchkarev V., Handjiski B., Metz M., Hibino T., Soma T., Dotto G. P., Paus R. (2000) FASEB J. 14, 752–760 [DOI] [PubMed] [Google Scholar]
- 64. Cho Y. M., Woodard G. L., Dunbar M., Gocken T., Jimènez J. A., Foley J. (2003) J. Invest. Dermatol. 120, 715–727 [DOI] [PubMed] [Google Scholar]
- 65. Yuhki M., Yamada M., Kawano M., Iwasato T., Itohara S., Yoshida H., Ogawa M., Mishina Y. (2004) Development 131, 1825–1833 [DOI] [PubMed] [Google Scholar]
- 66. Vauclair S., Nicolas M., Barrandon Y., Radtke F. (2005) Dev. Biol. 284, 184–193 [DOI] [PubMed] [Google Scholar]
- 67. Tong X., Coulombe P. A. (2006) Genes Dev. 20, 1353–1364 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Pena J. C., Kelekar A., Fuchs E. V., Thompson C. B. (1999) EMBO J. 18, 3596–3603 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Shridas P., Bailey W. M., Gizard F., Oslund R. C., Gelb M. H., Bruemmer D., Webb N. R. (2010) Arterioscler Thromb. Vasc. Biol. 30, 2014–2021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Xu L., Han C., Lim K., Wu T. (2006) Cancer Res. 66, 11859–11868 [DOI] [PubMed] [Google Scholar]
- 71. Ninomiya Y., Yasuda T., Kawamoto M., Yuge O., Okazaki Y. (2007) J. Steroid Biochem. Mol. Biol. 103, 44–50 [DOI] [PubMed] [Google Scholar]
- 72. Li N., Rivéra-Bermúdez M. A., Zhang M., Tejada J., Glasson S. S., Collins-Racie L. A., Lavallie E. R., Wang Y., Chang K. C., Nagpal S., Morris E. A., Flannery C. R., Yang Z. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 3734–3739 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Glotzer D. J., Zelzer E., Olsen B. R. (2008) Dev. Biol. 315, 459–473 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Jong M. C., Gijbels M. J., Dahlmans V. E., Gorp P. J., Koopman S. J., Ponec M., Hofker M. H., Havekes L. M. (1998) J. Clin. Invest. 101, 145–152 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75. Scott G. A., Jacobs S. E., Pentland A. P. (2006) J. Invest. Dermatol. 126, 855–861 [DOI] [PubMed] [Google Scholar]
- 76. Kang H. Y., Chung E., Lee M., Cho Y., Kang W. H. (2004) Br. J. Dermatol. 150, 462–468 [DOI] [PubMed] [Google Scholar]
- 77. Lee J. S., Choi Y. M., Kang H. Y. (2007) Exp. Dermatol. 16, 118–123 [DOI] [PubMed] [Google Scholar]
- 78. Mao-Qiang M., Jain M., Feingold K. R., Elias P. M. (1996) J. Invest. Dermatol. 106, 57–63 [DOI] [PubMed] [Google Scholar]
- 79. Fluhr J. W., Kao J., Jain M., Ahn S. K., Feingold K. R., Elias P. M. (2001) J. Invest. Dermatol. 117, 44–51 [DOI] [PubMed] [Google Scholar]
- 80. Fluhr J. W., Behne M. J., Brown B. E., Moskowitz D. G., Selden C., Mao-Qiang M., Mauro T. M., Elias P. M., Feingold K. R. (2004) J. Invest. Dermatol. 122, 320–329 [DOI] [PubMed] [Google Scholar]
- 81. Huelsken J., Vogel R., Erdmann B., Cotsarelis G., Birchmeier W. (2001) Cell 105, 533–545 [DOI] [PubMed] [Google Scholar]
- 82. Nakamura Y., Fukami K., Yu H., Takenaka K., Kataoka Y., Shirakata Y., Nishikawa S., Hashimoto K., Yoshida N., Takenawa T. (2003) EMBO J. 22, 2981–2991 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.